KR100196256B1 - 서방성 약물 제형 - Google Patents
서방성 약물 제형 Download PDFInfo
- Publication number
- KR100196256B1 KR100196256B1 KR1019920702558A KR920702558A KR100196256B1 KR 100196256 B1 KR100196256 B1 KR 100196256B1 KR 1019920702558 A KR1019920702558 A KR 1019920702558A KR 920702558 A KR920702558 A KR 920702558A KR 100196256 B1 KR100196256 B1 KR 100196256B1
- Authority
- KR
- South Korea
- Prior art keywords
- membrane
- drug
- consisting essentially
- colon
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000013270 controlled release Methods 0.000 title description 4
- 239000013583 drug formulation Substances 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 47
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 239000012528 membrane Substances 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 230000001419 dependent effect Effects 0.000 claims abstract description 18
- 210000001072 colon Anatomy 0.000 claims abstract description 16
- 239000012530 fluid Substances 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 230000002496 gastric effect Effects 0.000 claims abstract description 11
- 210000000813 small intestine Anatomy 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 239000008185 minitablet Substances 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 11
- 229920001249 ethyl cellulose Polymers 0.000 claims description 11
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 7
- -1 hydroxypropylmethyl Chemical group 0.000 claims description 7
- 102000008857 Ferritin Human genes 0.000 claims description 4
- 108050000784 Ferritin Proteins 0.000 claims description 4
- 238000008416 Ferritin Methods 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
- 229960004015 calcitonin Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 125000005591 trimellitate group Chemical group 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 239000003246 corticosteroid Substances 0.000 abstract description 3
- 229960001334 corticosteroids Drugs 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 abstract description 3
- 235000019477 peppermint oil Nutrition 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000003826 tablet Substances 0.000 description 10
- 229920003137 Eudragit® S polymer Polymers 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000007931 coated granule Substances 0.000 description 8
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 8
- 239000008187 granular material Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical group NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 229940069498 intestinal antiinfectives Drugs 0.000 description 1
- 229940069495 intestinal antiinflammatory agent Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT02005490A IT1246382B (it) | 1990-04-17 | 1990-04-17 | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| IT20054A/90 | 1990-04-17 | ||
| PCT/EP1991/000688 WO1991016042A1 (en) | 1990-04-17 | 1991-04-09 | Controlled release drug formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930700077A KR930700077A (ko) | 1993-03-13 |
| KR100196256B1 true KR100196256B1 (ko) | 1999-06-15 |
Family
ID=11163447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920702558A Expired - Fee Related KR100196256B1 (ko) | 1990-04-17 | 1991-04-09 | 서방성 약물 제형 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5900252A (cg-RX-API-DMAC7.html) |
| EP (2) | EP0453001A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP3194974B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100196256B1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE144138T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU654277B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2035155A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69122751T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0524989T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2093097T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3021847T3 (cg-RX-API-DMAC7.html) |
| IE (1) | IE911271A1 (cg-RX-API-DMAC7.html) |
| IT (1) | IT1246382B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ237823A (cg-RX-API-DMAC7.html) |
| PT (1) | PT97370B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2111743C1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG46584A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW223022B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1991016042A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA912792B (cg-RX-API-DMAC7.html) |
Families Citing this family (418)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| IT1260505B (it) * | 1992-06-01 | 1996-04-09 | Poli Ind Chimica Spa | Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon |
| WO1995016451A1 (fr) * | 1992-06-22 | 1995-06-22 | Franck Arno Gouchet | Comprimes a liberation controlee de 4-asa |
| FR2692484B1 (fr) * | 1992-06-22 | 1995-06-30 | Gouchet Franck | Nouvelle forme galenique de 4-asa a liberation controlee. |
| AU670958B2 (en) * | 1992-08-05 | 1996-08-08 | Mayne Pharma International Pty Ltd | Pelletised pharmaceutical composition |
| EP0653935B1 (en) * | 1992-08-05 | 2002-05-08 | F.H. FAULDING & CO. LIMITED | Pelletised pharmaceutical composition |
| US5358502A (en) | 1993-02-25 | 1994-10-25 | Pfizer Inc | PH-triggered osmotic bursting delivery devices |
| US5914132A (en) * | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| IT1265092B1 (it) * | 1993-05-31 | 1996-10-30 | Giuliani Spa | Preparato per uso come integratore alimentare, o dietetico,a rilascio mirato nel colon |
| DE4332394A1 (de) * | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
| US5523095A (en) * | 1993-12-15 | 1996-06-04 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends |
| US5536505A (en) * | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
| AU689250B2 (en) * | 1994-04-22 | 1998-03-26 | Astellas Pharma Inc. | Colon-specific drug release system |
| AT403988B (de) * | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
| US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| CA2240281C (en) * | 1995-12-21 | 2007-02-27 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases |
| US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| AUPO247496A0 (en) | 1996-09-23 | 1996-10-17 | Resmed Limited | Assisted ventilation to match patient respiratory need |
| WO1998026767A2 (en) * | 1996-12-17 | 1998-06-25 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
| WO1998027967A1 (en) * | 1996-12-20 | 1998-07-02 | Dumex-Alpharma A/S | Release-controlled coated tablets |
| US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5788987A (en) | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| DK1017392T3 (da) * | 1997-09-25 | 2002-10-21 | Bayer Ag | Lægemiddel |
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6962717B1 (en) | 1999-01-29 | 2005-11-08 | Disphar International B.V. | Pharmaceutical compositions |
| US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
| US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| RU2246293C2 (ru) | 1999-06-14 | 2005-02-20 | Космо С.П.А. | Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом |
| US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
| US7897140B2 (en) * | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
| US6451345B1 (en) | 2000-01-20 | 2002-09-17 | Eurand Pharmaceuticals Ltd. | Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| IT1318625B1 (it) * | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
| AU2001284434A1 (en) | 2000-09-06 | 2002-03-22 | Mitsubishi Pharma Corporation | Granular preparations for oral administration |
| RU2191782C2 (ru) * | 2000-09-21 | 2002-10-27 | Институт нефтехимии и катализа АН РБ и УНЦ РАН | Способ получения модифицированной гиалуроновой кислоты |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| WO2003045356A1 (en) * | 2000-11-20 | 2003-06-05 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings |
| US6932861B2 (en) | 2000-11-28 | 2005-08-23 | Fmc Corporation | Edible PGA coating composition |
| TR200300731T2 (tr) | 2000-11-28 | 2004-08-23 | Fmc Corporation | Yenebilir PGA kaplama bileşimi |
| US20030190360A1 (en) | 2001-03-13 | 2003-10-09 | Baichwal Anand R. | Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment |
| RU2324475C2 (ru) * | 2001-04-10 | 2008-05-20 | Сан Фармасьютикал Индастриз Лимитед | Состав, выделяемый в импульсном режиме в заданное время |
| KR20010069756A (ko) * | 2001-05-08 | 2001-07-25 | 유형선 | 소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법 |
| US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| US9358214B2 (en) * | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| AR036797A1 (es) | 2001-10-15 | 2004-10-06 | Ferring Bv | Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn |
| EP1446110A2 (en) * | 2001-10-16 | 2004-08-18 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
| EP1455751A1 (en) * | 2001-12-20 | 2004-09-15 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
| RU2220716C1 (ru) * | 2002-04-24 | 2004-01-10 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова | Способ получения микрокапсул, содержащих живые микроорганизмы |
| US8829198B2 (en) * | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
| CA2490692A1 (en) | 2002-06-27 | 2004-01-08 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| EP1606291A2 (en) * | 2002-07-02 | 2005-12-21 | Health Research, Inc. | Efficient synthesis of pyropheophorbide a and its dervatives |
| GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
| AU2003251377A1 (en) * | 2002-08-14 | 2004-03-03 | Quest International Services B.V. | Compositions comprising encapsulated material |
| EP1393706A1 (en) * | 2002-08-14 | 2004-03-03 | Quest International B.V. | Fragranced compositions comprising encapsulated material |
| AU2003284942A1 (en) * | 2002-10-30 | 2004-06-07 | Pharmacia Corporation | Oral extended release tablets and methods of making and using the same |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
| BRPI0408805A (pt) * | 2003-03-31 | 2006-03-28 | Pliva Lachema As | composição farmacêutica contendo complexo de platina e método de fabricação da mesma |
| US20070042143A1 (en) | 2003-04-23 | 2007-02-22 | Ferring B.V. | Sachet for a pharmaceutical composition |
| WO2004099162A1 (en) * | 2003-04-30 | 2004-11-18 | Ricerca Biosciences, Llc. | Polycyclic diazodioxide-based bcl-2 protein antagonist |
| WO2004099158A1 (en) * | 2003-04-30 | 2004-11-18 | Ricerca Biosciences, Llc. | Monocyclic diazodioxide based bcl-2 protein antagonists |
| CN102584813B (zh) * | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| US20090227647A1 (en) * | 2008-03-05 | 2009-09-10 | Thomas Lake | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes |
| US8916598B2 (en) | 2003-05-30 | 2014-12-23 | Proteotech Inc | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies |
| US20100331380A1 (en) * | 2009-06-29 | 2010-12-30 | Esposito Luke A | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies |
| CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
| US7057100B2 (en) * | 2003-06-26 | 2006-06-06 | The J.C. Robinson Seed Co. | Inbred corn line W23129 |
| US7825106B2 (en) | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| CA2539051C (en) | 2003-09-19 | 2014-08-12 | Penwest Pharmaceuticals Co. | Delayed release dosage forms |
| CA2537103C (en) | 2003-11-04 | 2010-01-19 | Shire Laboratories, Inc. | Once daily dosage forms of trospium |
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| EP1547601A1 (en) | 2003-12-23 | 2005-06-29 | Ferring B.V. | Coating method |
| WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| US20050142197A1 (en) * | 2003-12-31 | 2005-06-30 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| ATE500821T1 (de) * | 2003-12-31 | 2011-03-15 | Cima Labs Inc | Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon |
| US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
| WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| US7868033B2 (en) | 2004-05-20 | 2011-01-11 | Foldrx Pharmaceuticals, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| WO2006009876A2 (en) * | 2004-06-17 | 2006-01-26 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| JP2008505916A (ja) * | 2004-07-09 | 2008-02-28 | メタバシス・セラピューティクス・インコーポレイテッド | チロシンホスファターゼの酸素／窒素複素環阻害剤 |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| WO2006028970A1 (en) | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| NZ588431A (en) | 2004-09-17 | 2012-02-24 | Whitehead Biomedical Inst | Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity |
| US20060067889A1 (en) * | 2004-09-27 | 2006-03-30 | Light Sciences Corporation | Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US9149439B2 (en) * | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| US8222257B2 (en) | 2005-04-01 | 2012-07-17 | The Regents Of The University Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US20100098640A1 (en) * | 2005-06-20 | 2010-04-22 | Cohen Seth M | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation |
| WO2008051197A2 (en) * | 2005-09-20 | 2008-05-02 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| US8138361B2 (en) * | 2005-12-28 | 2012-03-20 | The Trustees Of The University Of Pennsylvania | C-10 carbamates of taxanes |
| EP2013182B1 (en) * | 2006-03-13 | 2013-09-04 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolones as gsk-3 inhibitors |
| CN101460161A (zh) * | 2006-03-29 | 2009-06-17 | 弗尔德里克斯制药股份有限公司 | α-突触核蛋白毒性的抑制 |
| JP5457830B2 (ja) | 2006-04-03 | 2014-04-02 | オディディ，イサ | オルガノゾル被膜を含む制御放出送達デバイス |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| US20080076743A1 (en) | 2006-08-03 | 2008-03-27 | Nitec Pharma Ag | Delayed-Release Glucocorticoid treatment of Rheumatoid Disease |
| TWI405771B (zh) | 2006-08-28 | 2013-08-21 | Kyowa Hakko Kirin Co Ltd | 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體 |
| CA2661172A1 (en) * | 2006-09-04 | 2008-05-29 | Panacea Biotec Limited | Programmable buoyant delivery technology |
| PL2066662T3 (pl) | 2006-09-21 | 2013-05-31 | Kyorin Seiyaku Kk | Inhibitory hydrolaz serynowych |
| CN101687788A (zh) | 2006-10-19 | 2010-03-31 | 奥斯拜客斯制药有限公司 | 取代的吲哚 |
| US20100137421A1 (en) * | 2006-11-08 | 2010-06-03 | Emmanuel Theodorakis | Small molecule therapeutics, synthesis of analogues and derivatives and methods of use |
| EP2121676A1 (en) | 2006-12-19 | 2009-11-25 | Auspex Pharmaceuticals, Inc. | Preperation and utility of ccr5 inhibitors |
| CA2671766A1 (en) * | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
| WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
| PT2144604E (pt) * | 2007-02-28 | 2011-10-19 | Conatus Pharmaceuticals Inc | Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830 |
| HRP20161581T1 (hr) | 2007-03-15 | 2016-12-30 | Auspex Pharmaceuticals, Inc. | DEUTERIRANI d9-VENLAFAKSI |
| AU2008241470B2 (en) | 2007-04-16 | 2013-11-07 | Corium Pharma Solutions, Inc. | Solvent-cast microneedle arrays containing active |
| US7892776B2 (en) | 2007-05-04 | 2011-02-22 | The Regents Of The University Of California | Screening assay to identify modulators of protein kinase A |
| PT2152250T (pt) * | 2007-05-07 | 2019-12-12 | Evonik Operations Gmbh | Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco |
| EP2170062A4 (en) * | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES |
| MX2010002667A (es) * | 2007-09-11 | 2010-04-01 | Activx Biosciences Inc | Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3. |
| CN101855229A (zh) | 2007-09-12 | 2010-10-06 | 埃迪威克斯生物科学公司 | 作为gsk-3抑制剂的螺环状氨基喹诺酮 |
| US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
| WO2009048607A1 (en) | 2007-10-10 | 2009-04-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
| CA2702356C (en) * | 2007-10-12 | 2014-02-11 | Takeda Pharmaceuticals North America, Inc. | Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake |
| US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
| AU2008327615B2 (en) | 2007-11-21 | 2014-08-21 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
| KR101601997B1 (ko) | 2008-03-17 | 2016-03-17 | 암비트 바이오사이언시즈 코포레이션 | Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법 |
| US20120034157A1 (en) * | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
| CN101658533A (zh) * | 2008-08-29 | 2010-03-03 | 首都医科大学宣武医院 | 抗肿瘤药物的干细胞递送 |
| WO2010040113A1 (en) | 2008-10-03 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| NZ592673A (en) * | 2008-11-13 | 2013-01-25 | Giuliani Int Ltd | Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease |
| TWI494108B (zh) * | 2009-01-26 | 2015-08-01 | Nitec Pharma Ag | 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途 |
| NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
| WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| EP2401267B1 (en) | 2009-02-27 | 2014-01-15 | Ambit Biosciences Corporation | Jak kinase modulating quinazoline derivatives and their use in methods |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| WO2010105016A1 (en) | 2009-03-11 | 2010-09-16 | Ambit Biosciences Corp. | Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| CA2755120C (en) * | 2009-03-11 | 2017-05-16 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
| WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
| TW201038567A (en) | 2009-03-27 | 2010-11-01 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| KR101687144B1 (ko) | 2009-04-22 | 2016-12-15 | 액시킨 파마수티컬스 인코포레이티드 | 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제 |
| SG2014005110A (en) | 2009-04-22 | 2014-03-28 | Axikin Pharmaceuticals Inc | Arylsulfonamide ccr3 antagonists |
| JP2012524789A (ja) | 2009-04-22 | 2012-10-18 | アクシキン ファーマシューティカルズ インコーポレーテッド | ２，５−二置換アリールスルホンアミドｃｃｒ３アンタゴニスト |
| WO2011003870A2 (en) | 2009-07-06 | 2011-01-13 | Creabilis S.A. | Mini-pegylated corticosteroids, compositions including same, and methods of making and using same |
| AR080945A1 (es) | 2009-07-07 | 2012-05-23 | Pathway Therapeutics Inc | Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer |
| CA2767168C (en) | 2009-07-08 | 2019-04-09 | Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals | Sodium thiosulfate-containing pharmaceutical compositions |
| US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
| CN102470127A (zh) | 2009-08-19 | 2012-05-23 | 埃姆比特生物科学公司 | 联芳基化合物和其使用方法 |
| WO2011056566A2 (en) | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
| WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
| RU2419422C1 (ru) * | 2009-11-05 | 2011-05-27 | Федеральное государственное учреждение науки Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора РФ | Способ коррекции функциональных нарушений билиарного тракта у детей, больных острыми кишечными инфекциями |
| WO2011057214A2 (en) | 2009-11-09 | 2011-05-12 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| WO2011069002A1 (en) | 2009-12-02 | 2011-06-09 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
| TWI471146B (zh) | 2009-12-02 | 2015-02-01 | Aptalis Pharma Ltd | 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物 |
| CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| SG181896A1 (en) * | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| EP2538930B1 (en) | 2010-02-23 | 2016-06-15 | Da Volterra | Formulations for oral delivery of adsorbents in the gut |
| CA2791964A1 (en) | 2010-03-02 | 2011-09-09 | Axikin Pharmaceuticals, Inc. | Isotopically enriched arylsulfonamide ccr3 antagonists |
| WO2011112689A2 (en) | 2010-03-11 | 2011-09-15 | Ambit Biosciences Corp. | Saltz of an indazolylpyrrolotriazine |
| MX336559B (es) | 2010-03-17 | 2016-01-25 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida. |
| WO2011140274A2 (en) | 2010-05-04 | 2011-11-10 | Corium International, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
| WO2011150201A2 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl amide compounds and methods of use thereof |
| WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
| AU2011261501B2 (en) | 2010-06-01 | 2016-01-21 | Biotheryx, Inc. | Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone |
| MX2012013879A (es) | 2010-06-01 | 2013-04-03 | Biotheryx Inc | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. |
| JP5855095B2 (ja) | 2010-06-07 | 2016-02-09 | ノボメディックス, エルエルシーNovomedix, Llc | フラニル化合物およびその使用 |
| NZ605860A (en) | 2010-07-19 | 2015-04-24 | Summa Health System | Use of vitamin c, and chromium-free vitamin k or 2-methyl-1,4-naphthalendione, and compositions thereof for treating a polycystic disease |
| US20130317045A1 (en) | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| WO2012030912A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| MX2013002383A (es) | 2010-09-01 | 2013-07-05 | Ambit Biosciences Corp | Sales bromhidrato de una pirazolilaminoquinazolina. |
| US20120053176A1 (en) | 2010-09-01 | 2012-03-01 | Ambit Biosciences Corp. | Adenosine a3 receptor modulating compounds and methods of use thereof |
| AU2011296024B2 (en) | 2010-09-01 | 2015-05-28 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
| US20130225615A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| US20130225614A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
| US20130296363A1 (en) | 2010-09-01 | 2013-11-07 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
| US8703943B2 (en) | 2010-09-01 | 2014-04-22 | Ambit Biosciences Corporation | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
| WO2012030924A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
| WO2012044641A1 (en) | 2010-09-29 | 2012-04-05 | Pathway Therapeutics Inc. | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| CA2814011A1 (en) | 2010-10-11 | 2012-04-19 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide ccr3 antagonists |
| EP2648676A4 (en) | 2010-12-06 | 2016-05-04 | Follica Inc | METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH |
| WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
| WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| JP2014503597A (ja) | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | シチジンアナログの医薬組成物及びその使用方法 |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| KR101940831B1 (ko) | 2011-03-28 | 2019-01-21 | 메이 파마, 아이엔씨. | (알파-치환된 아르알킬아미노 및 헤테로아릴알킬아미노)피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸, 이들을 함유하는 약학 조성물, 및 증식성 질병의 치료에 사용하기 위한 이들 화합물 |
| WO2012135166A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| WO2012135175A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| JP5813391B2 (ja) * | 2011-06-24 | 2015-11-17 | 日東電工株式会社 | 粒子製剤の製造方法 |
| WO2012177962A1 (en) | 2011-06-23 | 2012-12-27 | Map Pharmaceuticals, Inc. | Novel fluoroergoline analogs |
| US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| TWI650321B (zh) | 2011-10-14 | 2019-02-11 | 美商安比特生物科學公司 | 雜環化合物及其使用方法 |
| EP2599477A1 (en) | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| AU2012355982A1 (en) | 2011-12-19 | 2014-07-10 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
| WO2013095708A1 (en) | 2011-12-21 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel neuromodulatory compounds |
| JP2012107058A (ja) * | 2012-02-27 | 2012-06-07 | Warner Chilcott Co Llc | 複数のコーティングを有する医薬剤形 |
| US9611253B2 (en) | 2012-02-29 | 2017-04-04 | Ambit Biosciences Corporation | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith |
| AU2013229990B2 (en) * | 2012-03-07 | 2017-07-06 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
| JP6134376B2 (ja) | 2012-03-16 | 2017-05-24 | アクシキン ファーマシューティカルズ インコーポレーテッド | ３，５−ジアミノピラゾールキナーゼ阻害剤 |
| BR112014024159A2 (pt) | 2012-03-29 | 2017-06-20 | Therabiome Llc | Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice. |
| PL2844637T3 (pl) | 2012-05-02 | 2018-09-28 | Boehringer Ingelheim International Gmbh | Podstawione 3-haloalliloaminowe inhibitory ssao i ich zastosowania |
| CN103417380B (zh) * | 2012-05-22 | 2016-01-06 | 正和制药股份有限公司 | 具有肠溶膜衣的硬胶囊 |
| WO2013187965A1 (en) | 2012-06-14 | 2013-12-19 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of stat3 |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| AU2013295848B2 (en) | 2012-07-25 | 2018-05-24 | Celldex Therapeutics, Inc. | Anti-KIT antibodies and uses thereof |
| US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
| WO2014033077A1 (en) | 2012-08-28 | 2014-03-06 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets |
| JP2015527396A (ja) | 2012-09-07 | 2015-09-17 | アクシキン ファーマシューティカルズ インコーポレーテッド | 同位体濃縮されたアリールスルホンアミドｃｃｒ３アンタゴニスト |
| WO2014055647A1 (en) | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| CA2890177A1 (en) | 2012-11-08 | 2014-05-15 | Summa Health System | Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing |
| WO2014085633A1 (en) | 2012-11-30 | 2014-06-05 | Novomedix, Llc | Substituted biaryl sulfonamides and the use thereof |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| BR112015014964A2 (pt) | 2012-12-21 | 2017-07-11 | Map Pharmaceuticals Inc | novos derivados de metisergida |
| KR102265808B1 (ko) | 2012-12-21 | 2021-06-16 | 코리움, 인크. | 치료제의 전달을 위한 마이크로어레이 및 그것의 사용방법 |
| AU2014205324A1 (en) | 2013-01-11 | 2015-07-30 | Mayo Foundation For Medical Education And Research | Vitamins C and K for treating polycystic diseases |
| EP2968887B1 (en) | 2013-03-12 | 2022-05-04 | Corium, Inc. | Microprojection applicators |
| WO2014152338A1 (en) | 2013-03-14 | 2014-09-25 | Kabadi Mohan | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| WO2014152450A1 (en) | 2013-03-15 | 2014-09-25 | Warner Chilcott Company, Llc | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
| EP2968116A1 (en) | 2013-03-15 | 2016-01-20 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
| MX2015012433A (es) | 2013-03-15 | 2016-02-03 | Corium Int Inc | Matriz de microestructura para suministro de agentes activos. |
| JP2016512754A (ja) | 2013-03-15 | 2016-05-09 | コリウム インターナショナル， インコーポレイテッド | 治療剤の送達のためのマイクロアレイ、使用方法および製造方法 |
| CN105246458B (zh) | 2013-03-15 | 2020-09-15 | 考里安公司 | 用于治疗剂递送的微阵列及其使用方法 |
| EP4194028A1 (en) | 2013-03-15 | 2023-06-14 | Corium Pharma Solutions, Inc. | Multiple impact microprojection applicators |
| CA2914369C (en) | 2013-06-06 | 2023-02-14 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
| KR20160055170A (ko) | 2013-08-30 | 2016-05-17 | 암비트 바이오사이언시즈 코포레이션 | 바이아릴 아세트아미드 화합물 및 이의 사용 방법 |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015127351A1 (en) | 2014-02-24 | 2015-08-27 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| KR20240064750A (ko) | 2014-03-20 | 2024-05-13 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| JP6568926B2 (ja) | 2014-03-20 | 2019-08-28 | カペラ セラピューティクス，インコーポレーテッド | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
| EP3444011A1 (en) | 2014-05-12 | 2019-02-20 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with emricasan |
| RS61678B1 (sr) | 2014-05-28 | 2021-05-31 | Agenus Inc | Anti-gitr antitela i postupci za njihovu primenu |
| WO2015195474A1 (en) | 2014-06-18 | 2015-12-23 | Biotheryx, Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| JP6543342B2 (ja) | 2014-08-14 | 2019-07-10 | アルハマドシャー，マモウン，エム． | 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション |
| EP3193828B8 (en) | 2014-08-29 | 2023-04-05 | Corium Pharma Solutions, Inc. | Microstructure array for delivery of active agents |
| EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
| EP3191100A4 (en) | 2014-09-12 | 2018-05-30 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| US20170354639A1 (en) | 2014-10-24 | 2017-12-14 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
| KR102693806B1 (ko) | 2014-12-11 | 2024-08-09 | 피에르 파브르 메디카먼트 | 항-c10orf54 항체들 및 그들의 용도들 |
| ES2862701T3 (es) | 2014-12-22 | 2021-10-07 | Univ Rockefeller | Anticuerpos agonistas anti-MERTK y usos de los mismos |
| MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
| CN107405346A (zh) | 2015-01-20 | 2017-11-28 | Xoc制药股份有限公司 | 异麦角灵化合物及其用途 |
| BR112017015487A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo |
| HK1247203A1 (zh) | 2015-01-28 | 2018-09-21 | 上海复旦张江生物医药股份有限公司 | 取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法 |
| LT3265123T (lt) | 2015-03-03 | 2023-01-25 | Kymab Limited | Antikūnai, naudojimas ir būdai |
| RS60792B1 (sr) | 2015-05-29 | 2020-10-30 | Agenus Inc | Anti-ctla-4 antitela i postupci za njihovu primenu |
| CN107921032B (zh) | 2015-06-23 | 2021-09-24 | 纽罗克里生物科学有限公司 | 用于治疗神经学疾病或病症的vmat2抑制剂 |
| WO2017004067A1 (en) | 2015-06-29 | 2017-01-05 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| JP7109360B2 (ja) | 2015-10-30 | 2022-07-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | バルベナジン塩およびその多形体 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| CN108883103A (zh) | 2015-12-02 | 2018-11-23 | 阿斯特来亚治疗有限责任公司 | 哌啶基痛敏肽受体化合物 |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| KR20180101418A (ko) | 2015-12-31 | 2018-09-12 | 코나터스 파마슈티칼스, 인크. | 간 질환의 치료에서의 카스파제 억제제의 사용 방법 |
| MX385964B (es) | 2016-01-08 | 2025-03-18 | Celgene Corp | Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos. |
| EP3808346B1 (en) | 2016-01-08 | 2023-07-19 | Celgene Corporation | Antiproliferative compounds for use in the treatment of leukemia |
| US10960013B2 (en) | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
| JP2019510085A (ja) | 2016-03-08 | 2019-04-11 | ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌治療のためのナノ粒子ならびに方法および化合物 |
| JP2019513151A (ja) | 2016-03-08 | 2019-05-23 | ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | カンプトテシン誘導体及びその使用 |
| CA3017797A1 (en) | 2016-03-17 | 2017-09-21 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
| CN108884019A (zh) | 2016-04-11 | 2018-11-23 | 克雷西奥生物科技有限公司 | 氘代氯胺酮衍生物 |
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| RU2738114C2 (ru) | 2016-04-19 | 2020-12-08 | Конарис Рисёрч Инститьют Аг | Пероральные фармацевтические композиции никотинамида |
| AR108231A1 (es) * | 2016-04-19 | 2018-08-01 | Ferring Bv | Composiciones farmacéuticas orales de mesalazina |
| EP4190357A1 (en) | 2016-05-13 | 2023-06-07 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| TWI753910B (zh) | 2016-05-16 | 2022-02-01 | 美商拜歐斯瑞克斯公司 | 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途 |
| NZ749355A (en) | 2016-05-27 | 2023-04-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US10919904B2 (en) | 2016-08-17 | 2021-02-16 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
| US20190201409A1 (en) | 2016-09-19 | 2019-07-04 | Mei Pharma, Inc. | Combination therapy |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JP7045724B2 (ja) | 2016-11-07 | 2022-04-01 | ニューラクル サイエンス カンパニー リミテッド | 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途 |
| WO2018089692A1 (en) | 2016-11-09 | 2018-05-17 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
| CN110167542A (zh) | 2016-11-09 | 2019-08-23 | 诺沃梅迪科斯有限公司 | 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法 |
| WO2018102252A1 (en) | 2016-11-30 | 2018-06-07 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
| US10799503B2 (en) | 2016-12-01 | 2020-10-13 | Ignyta, Inc. | Methods for the treatment of cancer |
| JP2020500875A (ja) | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| MD3551660T2 (ro) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anticorpi anti-CTLA-4 și procedee de utilizare a acestora |
| EA201991782A1 (ru) | 2017-01-27 | 2021-09-23 | Нейрокрин Байосайенсиз, Инк. | Способы введения некоторых vmat2-ингибиторов |
| MX2021015220A (es) | 2017-02-17 | 2022-12-01 | Eidos Therapeutics Inc | Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo. |
| AU2018220515B2 (en) | 2017-02-17 | 2022-06-30 | DayLife LLC | Universal antivenom |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| EP3601351A1 (en) | 2017-03-27 | 2020-02-05 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| SMT202300243T1 (it) | 2017-05-01 | 2023-11-13 | Agenus Inc | Anticorpi anti-tigit e relativi metodi d'uso |
| JOP20190219A1 (ar) | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| IL270654B2 (en) * | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
| US11560425B2 (en) | 2017-06-27 | 2023-01-24 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies for treating cancers |
| AU2018291082B2 (en) | 2017-06-27 | 2025-05-29 | Neuracle Science Co., Ltd. | Anti-FAM19A5 antibodies and uses thereof |
| JP6904616B2 (ja) | 2017-06-27 | 2021-07-21 | ニューラクル サイエンス カンパニー リミテッド | 緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途 |
| EP3645039A4 (en) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS |
| EP4265257A1 (en) | 2017-09-01 | 2023-10-25 | East Carolina University | Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer |
| ES3024932T3 (en) | 2017-09-20 | 2025-06-05 | Thiogenesis Therapeutics Inc | Compounds for the treatment of cysteamine sensitive disorders |
| EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
| CN111372567B (zh) | 2017-09-21 | 2024-03-15 | 纽罗克里生物科学有限公司 | 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 |
| WO2019069229A1 (en) | 2017-10-02 | 2019-04-11 | Neuracle Science Co., Ltd. | USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS |
| KR20200084864A (ko) | 2017-10-04 | 2020-07-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 면역조절성 올리고사카라이드 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019074492A1 (en) | 2017-10-10 | 2019-04-18 | Obrien Christopher F | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| EP3501503A1 (en) | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
| WO2019139871A1 (en) | 2018-01-10 | 2019-07-18 | Cura Therapeutics Llc | Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications |
| US11701334B2 (en) | 2018-01-10 | 2023-07-18 | Cura Therapeutics, Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
| UA130053C2 (uk) | 2018-03-23 | 2025-10-29 | Ейдос Терапьютікс, Інк. | Спосіб лікування транстиретинового амілоїдозу із застосуванням ag10 |
| WO2019207513A1 (en) | 2018-04-24 | 2019-10-31 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain |
| KR102585324B1 (ko) | 2018-05-08 | 2023-10-10 | 주식회사 뉴라클제네틱스 | 항-fam19a5 항체의 아데노-연관 바이러스(aav) 전달 |
| CN119569873A (zh) | 2018-05-10 | 2025-03-07 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体及其使用方法 |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| WO2020006341A1 (en) | 2018-06-29 | 2020-01-02 | Conatus Pharmaceuticals, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
| MX2021000786A (es) | 2018-07-20 | 2021-06-15 | Pf Medicament | Receptor para supresor de ig del dominio v de activación de células t (vista). |
| IL320987A (en) | 2018-08-15 | 2025-07-01 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| CN112804998A (zh) | 2018-08-17 | 2021-05-14 | 文涵治疗有限公司 | Ag10的制剂 |
| EP3860713A2 (en) | 2018-10-03 | 2021-08-11 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof |
| JP7211610B2 (ja) | 2018-10-16 | 2023-01-24 | ニューラクル サイエンス カンパニー リミテッド | 抗ｆａｍ１９ａ５抗体の用途 |
| CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
| IT201800011120A1 (it) | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| KR102757347B1 (ko) | 2018-12-27 | 2025-01-23 | 주식회사 뉴라클사이언스 | 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용 |
| SG11202104217QA (en) | 2019-01-02 | 2021-05-28 | Neuracle Science Co Ltd | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
| MX2021010003A (es) | 2019-02-26 | 2021-12-10 | Inspirna Inc | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. |
| US11597703B2 (en) | 2019-03-07 | 2023-03-07 | Histogen, Inc. | Caspase inhibitors and methods of use thereof |
| ES3036313T3 (en) | 2019-05-20 | 2025-09-17 | Nirvana Sciences Inc | Narrow emission dyes, compositions comprising same, and methods for making and using same |
| WO2020236818A1 (en) | 2019-05-20 | 2020-11-26 | Nirvana Sciences Inc. | Narrow emission dyes, compositions comprising same, and methods for making and using same |
| US20220274922A1 (en) | 2019-07-11 | 2022-09-01 | Cura Therapeutics, Llc | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications |
| WO2021007474A1 (en) | 2019-07-11 | 2021-01-14 | Cura Therapeutics, Llc | Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications |
| CA3148226A1 (en) | 2019-08-12 | 2021-02-18 | Massachusetts Institute Of Technology | Articles and methods for administration of therapeutic agents |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| AU2020335928A1 (en) | 2019-08-30 | 2022-02-17 | Agenus Inc. | Anti-CD96 antibodies and methods of use thereof |
| JP7566889B2 (ja) | 2019-09-16 | 2024-10-15 | ダイス・アルファ・インコーポレイテッド | Ｉｌ－１７ａモジュレーターおよびその使用 |
| CN114945409A (zh) | 2020-01-13 | 2022-08-26 | 新免疫技术有限公司 | 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法 |
| EP4093751A1 (en) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimeric polypeptides |
| AU2021217373A1 (en) | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
| US11529331B2 (en) | 2020-05-29 | 2022-12-20 | Boulder Bioscience Llc | Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane |
| US20230227466A1 (en) | 2020-06-18 | 2023-07-20 | Shy Therapeutics, Llc | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| US12024521B2 (en) | 2020-06-30 | 2024-07-02 | Prosetta Biosciences, Inc. | Isoquinoline derivatives, methods of synthesis and uses thereof |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| US20240101629A1 (en) | 2020-11-02 | 2024-03-28 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
| IL302482A (en) | 2020-11-05 | 2023-06-01 | Neoimmunetech Inc | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine |
| AU2021402911A1 (en) | 2020-12-14 | 2023-07-06 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| US20240309015A1 (en) | 2021-01-27 | 2024-09-19 | Shy Therapeutics, Llc | Methods for the Treatment of Fibrotic Disease |
| US20240124483A1 (en) | 2021-01-27 | 2024-04-18 | Shy Therapeutics, Llc | Methods for the Treatment of Fibrotic Disease |
| US20220280585A1 (en) * | 2021-03-05 | 2022-09-08 | Poopermints, LLC | Pharmaceutical composition containing champignon extract and peppermint and methods of use thereof |
| JP2024510196A (ja) | 2021-03-10 | 2024-03-06 | ダイス・モレキュールズ・エスブイ・インコーポレイテッド | アルファｖベータ６およびアルファｖベータ１インテグリン阻害剤およびその使用 |
| EP4326721A1 (en) | 2021-04-22 | 2024-02-28 | Protego Biopharma, Inc. | Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis |
| WO2022251533A1 (en) | 2021-05-27 | 2022-12-01 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
| WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
| JP2024520676A (ja) | 2021-06-02 | 2024-05-24 | ライエル・イミュノファーマ・インコーポレイテッド | Ｎｒ４ａ３欠損免疫細胞及びその使用 |
| IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Antibodies against interleukin 9 and methods of using them |
| WO2022266249A1 (en) | 2021-06-16 | 2022-12-22 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022266248A1 (en) | 2021-06-16 | 2022-12-22 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| EP4410311A4 (en) | 2021-09-29 | 2025-12-17 | Nbios Inc | FUSION PROTEIN WITH WINDED COIL CORE |
| JP2024539134A (ja) | 2021-10-22 | 2024-10-28 | プロセッタ バイオサイエンシズ， インク． | 新規な宿主標的汎呼吸器抗ウイルス小分子治療薬 |
| JP2024540411A (ja) | 2021-11-08 | 2024-10-31 | プロジェントス・セラピューティクス・インコーポレイテッド | 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用 |
| US20250099542A1 (en) | 2021-12-30 | 2025-03-27 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
| US11932665B2 (en) | 2022-01-03 | 2024-03-19 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
| JP2025501308A (ja) | 2022-01-03 | 2025-01-17 | ライラック セラピューティクス， インク． | 非環式チオールプロドラッグ |
| AU2022441090A1 (en) | 2022-02-17 | 2024-08-22 | Novelty Nobility Inc. | Antibody-drug conjugate. |
| CN118922189A (zh) | 2022-03-02 | 2024-11-08 | 线粒体能量有限公司 | 衍生自烟酸和核糖的新型前药 |
| CA3254863A1 (en) | 2022-03-30 | 2023-10-05 | Biomarin Pharmaceutical Inc. | DYSTROPHIN EXON-SKIPPING OLIGONUCLEOTIDES |
| GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
| AU2023252917A1 (en) | 2022-04-14 | 2024-11-28 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
| WO2023215781A1 (en) | 2022-05-05 | 2023-11-09 | Biomarin Pharmaceutical Inc. | Method of treating duchenne muscular dystrophy |
| IL316794A (en) | 2022-05-10 | 2025-01-01 | Biotheryx Inc | CDK protease inhibitors, pharmaceuticals and therapeutic applications |
| CA3253951A1 (en) | 2022-05-19 | 2023-11-23 | Lyell Immunopharma, Inc. | NR4A3 Targeted Polynucleotides and Their Uses |
| CA3267079A1 (en) | 2022-09-09 | 2024-03-14 | Innovo Therapeutics, Inc. | CK1α AND DOUBLE CK1α/GSPT1 DEGRADATION COMPOUNDS |
| WO2024073473A1 (en) | 2022-09-30 | 2024-04-04 | Boulder Bioscience Llc | Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury |
| JP2025537484A (ja) | 2022-10-21 | 2025-11-18 | ダイアゴナル・セラピューティクス・インコーポレイテッド | Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体 |
| EP4608834A1 (en) | 2022-10-26 | 2025-09-03 | Protego Biopharma, Inc. | Spirocycle containing pyridine compounds |
| WO2024092037A1 (en) | 2022-10-26 | 2024-05-02 | Protego Biopharma, Inc. | Spirocycle containing pyridone compounds |
| EP4608839A1 (en) | 2022-10-26 | 2025-09-03 | Protego Biopharma, Inc. | Spirocycle containing bicyclic heteroaryl compounds |
| KR20250089492A (ko) | 2022-11-07 | 2025-06-18 | 네오이뮨텍, 인코퍼레이티드 | 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법 |
| EP4626865A1 (en) | 2022-11-30 | 2025-10-08 | Protego Biopharma, Inc. | Cyclic pyrazole diamide ire1/xbp1s activators |
| EP4626864A1 (en) | 2022-11-30 | 2025-10-08 | Protego Biopharma, Inc. | Linear heteroaryl diamide ire1/xbp1s activators |
| AU2024240129A1 (en) | 2023-03-17 | 2025-10-09 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024194685A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| AU2024254039A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Hinge-modified bispecific antibodies |
| CN121127500A (zh) | 2023-04-07 | 2025-12-12 | 达科纳治疗有限公司 | 针对激活素a受体样1型(alk1)的双特异性激动性抗体 |
| WO2024226471A2 (en) | 2023-04-24 | 2024-10-31 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating stxbp1 disorders |
| WO2024233303A1 (en) | 2023-05-05 | 2024-11-14 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
| CN121263415A (zh) | 2023-05-09 | 2026-01-02 | 普罗根托斯治疗公司 | 杂环化合物及其用途 |
| US20250019450A1 (en) | 2023-05-19 | 2025-01-16 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to il12 receptor |
| WO2025010272A1 (en) | 2023-07-03 | 2025-01-09 | Neoimmunetech, Inc. | Heterodimeric fc molecules and uses thereof |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| US20250122182A1 (en) | 2023-09-27 | 2025-04-17 | Isosterix, Inc. | MYST Inhibitors |
| WO2025085416A1 (en) | 2023-10-16 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1 compounds and methods of use of the compounds |
| US20250179197A1 (en) | 2023-10-23 | 2025-06-05 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| GB2636969A (en) | 2023-11-24 | 2025-07-09 | Ontrack Therapeutics Ltd | Novel crystalline salt forms |
| WO2025133707A1 (en) | 2023-12-19 | 2025-06-26 | Vectory Therapeutics B.V. | Anti-tdp-43 antibodies and uses thereof |
| WO2025147691A1 (en) | 2024-01-04 | 2025-07-10 | Innovo Therapeutics, Inc. | Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025201633A1 (en) | 2024-03-26 | 2025-10-02 | Chen Gefei | An agent for reducing amyloid formation |
| WO2025255341A1 (en) | 2024-06-05 | 2025-12-11 | Protego Biopharma, Inc. | Tetrahydrofuranyl ire1/xbp1s activators |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3473490A (en) * | 1966-01-17 | 1969-10-21 | Camillo Corvi Mora | Producing chronoactive pharmaceutical granules |
| GB1468172A (en) * | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
| FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
| DK58983D0 (da) * | 1983-02-11 | 1983-02-11 | Leo Pharm Prod Ltd | Farmaceutisk praeparat |
| US4503030A (en) * | 1983-06-06 | 1985-03-05 | Alza Corporation | Device for delivering drug to certain pH environments |
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| EP0166315B1 (de) * | 1984-06-19 | 1989-08-23 | BASF Aktiengesellschaft | Magensaftresistent überzogene zylindrische Pankreatin-Mikrotabletten |
| DE3678641D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Partikel mit konstanter wirkstofffreisetzung. |
| JPS6261916A (ja) * | 1985-09-12 | 1987-03-18 | Fujisawa Pharmaceut Co Ltd | 持続性製剤 |
| AU591248B2 (en) * | 1986-03-27 | 1989-11-30 | Kinaform Technology, Inc. | Sustained-release pharaceutical preparation |
| US5238686A (en) * | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
| SE460945B (sv) * | 1987-01-15 | 1989-12-11 | Lejus Medical Ab | En multipel-unit-dos komposition av furosemid |
| JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| US4925676A (en) * | 1989-02-02 | 1990-05-15 | Warner-Lambert Company | Extended release gemfibrozil composition |
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US4983401A (en) * | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
-
1990
- 1990-04-17 IT IT02005490A patent/IT1246382B/it active IP Right Grant
-
1991
- 1991-01-29 EP EP91200173A patent/EP0453001A1/en not_active Withdrawn
- 1991-01-29 CA CA002035155A patent/CA2035155A1/en not_active Abandoned
- 1991-01-30 JP JP02778491A patent/JP3194974B2/ja not_active Expired - Lifetime
- 1991-04-09 SG SG1996006208A patent/SG46584A1/en unknown
- 1991-04-09 AU AU76798/91A patent/AU654277B2/en not_active Ceased
- 1991-04-09 DE DE69122751T patent/DE69122751T2/de not_active Expired - Fee Related
- 1991-04-09 WO PCT/EP1991/000688 patent/WO1991016042A1/en not_active Ceased
- 1991-04-09 ES ES91907396T patent/ES2093097T3/es not_active Expired - Lifetime
- 1991-04-09 JP JP91506876A patent/JPH05506217A/ja active Pending
- 1991-04-09 RU RU92016377A patent/RU2111743C1/ru active
- 1991-04-09 KR KR1019920702558A patent/KR100196256B1/ko not_active Expired - Fee Related
- 1991-04-09 DK DK91907396.5T patent/DK0524989T3/da active
- 1991-04-09 EP EP91907396A patent/EP0524989B1/en not_active Expired - Lifetime
- 1991-04-09 AT AT91907396T patent/ATE144138T1/de not_active IP Right Cessation
- 1991-04-15 PT PT97370A patent/PT97370B/pt not_active IP Right Cessation
- 1991-04-15 NZ NZ237823A patent/NZ237823A/en unknown
- 1991-04-15 ZA ZA912792A patent/ZA912792B/xx unknown
- 1991-04-15 CA CA002040471A patent/CA2040471A1/en not_active Abandoned
- 1991-04-16 IE IE127191A patent/IE911271A1/en unknown
- 1991-04-16 TW TW080102920A patent/TW223022B/zh active
-
1992
- 1992-11-06 US US07/972,660 patent/US5900252A/en not_active Expired - Fee Related
-
1996
- 1996-11-29 GR GR960403247T patent/GR3021847T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0524989B1 (en) | 1996-10-16 |
| ZA912792B (en) | 1992-12-30 |
| CA2035155A1 (en) | 1991-10-18 |
| ATE144138T1 (de) | 1996-11-15 |
| DE69122751D1 (de) | 1996-11-21 |
| NZ237823A (en) | 1992-09-25 |
| GR3021847T3 (en) | 1997-02-28 |
| AU7679891A (en) | 1991-11-11 |
| TW223022B (cg-RX-API-DMAC7.html) | 1994-05-01 |
| JPH04224517A (ja) | 1992-08-13 |
| US5900252A (en) | 1999-05-04 |
| EP0524989A1 (en) | 1993-02-03 |
| SG46584A1 (en) | 1998-02-20 |
| DK0524989T3 (da) | 1996-11-18 |
| AU654277B2 (en) | 1994-11-03 |
| IT9020054A0 (it) | 1990-04-17 |
| KR930700077A (ko) | 1993-03-13 |
| RU2111743C1 (ru) | 1998-05-27 |
| ES2093097T3 (es) | 1996-12-16 |
| IT9020054A1 (cg-RX-API-DMAC7.html) | 1991-10-17 |
| EP0453001A1 (en) | 1991-10-23 |
| DE69122751T2 (de) | 1997-02-13 |
| IE911271A1 (en) | 1991-10-23 |
| PT97370B (pt) | 1998-08-31 |
| CA2040471A1 (en) | 1991-10-18 |
| WO1991016042A1 (en) | 1991-10-31 |
| JP3194974B2 (ja) | 2001-08-06 |
| IT1246382B (it) | 1994-11-18 |
| JPH05506217A (ja) | 1993-09-16 |
| PT97370A (pt) | 1992-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100196256B1 (ko) | 서방성 약물 제형 | |
| JP6815358B2 (ja) | 時限パルス放出システム | |
| EP1123700B1 (en) | Timed pulsatile drug delivery systems | |
| WO2003051343A1 (en) | Pulsatile release histamine h2 antagonist dosage forms | |
| SE463850B (sv) | Elastiskt vattenhaltigt filmoeverdrag innehaallande hydroxipropylcellulosa och akrylhartser samt foerfarande foer dess framstaellning | |
| IL293651A (en) | A dosage form that includes an alkaline substance and a coating layer that dissolves in the intestines | |
| CN101287443A (zh) | pH控制的脉冲释放系统、其制备方法和用途 | |
| CN1956707B (zh) | 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型 | |
| JPH0710745A (ja) | 放出開始時間制御型腸デリバリー経口製剤 | |
| JP4771956B2 (ja) | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 | |
| Animesh et al. | Applicability and approaches of (Meth) acrylate copolymers (Eudragits) in novel drug delivery systems | |
| AU732210B2 (en) | Colonic delivery of weak acid drugs | |
| ZA200502318B (en) | Controlled release preparation | |
| EP0978275A1 (en) | Solid pharmaceutical dosage form with controlled drug release | |
| Menaga | Formulation and Evaluation of Targeted Drug Delivery Systems of Aceclofenac | |
| MXPA99003093A (en) | Colonic delivery of weak acid drugs | |
| AU2013273835A1 (en) | Timed, pulsatile release systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19921016 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19960326 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19921016 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19980610 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19981128 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19990219 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19990220 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20020129 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20030207 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20030207 Start annual number: 5 End annual number: 5 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20050111 |